Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab-Reference-Cited by-同舟云学术

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

Published:2011-02-04 Issue:6 Volume:186 Page:3762-3769
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Bologna Luca,Gotti Elisa,Manganini Massimiliano,Rambaldi Alessandro,Intermesoli Tamara,Introna Martino,Golay Josée

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference45 articles.

1. Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

2. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting

3. Rituximab dose-escalation trial in chronic lymphocytic leukemia.;O’Brien;J. Clin. Oncol.,2001

4. Anti-CD20 monoclonal antibodies: historical and future perspectives

5. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction.;Umana;ASH Ann. Meeting Abs.,2006

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of antibody glycosylation in autoimmune and alloimmune kidney diseases;Nature Reviews Nephrology;2024-07-03

2. Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept;Clinical Immunology;2024-07

3. pHLIP-fused PD-L1 engages avelumab to elicit NK cytotoxicity under acidic conditions;Heliyon;2024-05

4. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells;Frontiers in Immunology;2024-04-04

5. Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons;Expert Review of Clinical Immunology;2024-03-06